These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7554780)

  • 41. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population.
    Sundell IB; Nilsson TK; Hallmans G; Hellsten G; Dahlén GH
    Atherosclerosis; 1989 Nov; 80(1):9-16. PubMed ID: 2532510
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F
    Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness.
    Adly AA; Elbarbary NS; Ismail EA; Hassan SR
    J Diabetes Complications; 2014; 28(3):340-7. PubMed ID: 24581943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
    Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
    Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of high and low intensity aerobic conditioning programs on blood fibrinolysis and lipid profile.
    el-Sayed MS
    Blood Coagul Fibrinolysis; 1996 Jun; 7(4):484-90. PubMed ID: 8840002
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors affecting fibrinolytic potential: cardiovascular fitness, body composition, and lipoprotein(a).
    Szymanski LM; Durstine JL; Davis PG; Dowda M; Pate RR
    Metabolism; 1996 Nov; 45(11):1427-33. PubMed ID: 8931650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes.
    Weintrob N; Amitay I; Lilos P; Shalitin S; Lazar L; Josefsberg Z
    J Diabetes Complications; 2007; 21(1):13-9. PubMed ID: 17189869
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Measurable deficit of autonomic and sensory nerve function in asymptomatic diabetic patients.
    Piaggesi A; Castro Lòpez E; Bini L; Benzi L; Giampietro O; Schipani E; Navalesi R
    J Diabetes Complications; 1992; 6(3):157-62. PubMed ID: 1472740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
    Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
    Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.
    Glueck CJ; Glueck HI; Stroop D; Speirs J; Hamer T; Tracy T
    J Lab Clin Med; 1993 Oct; 122(4):412-20. PubMed ID: 8228555
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis.
    Segarra A; Chacón P; Martinez-Eyarre C; Argelaguer X; Vila J; Ruiz P; Fort J; Bartolomé J; Camps J; Moliner E; Pelegrí A; Marco F; Olmos A; Piera L
    J Am Soc Nephrol; 2001 Jun; 12(6):1255-1263. PubMed ID: 11373350
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction.
    Thøgersen AM; Söderberg S; Jansson JH; Dahlén G; Boman K; Nilsson TK; Lindahl B; Weinehall L; Stenlund H; Lundberg V; Johnson O; Ahrén B; Hallmans G
    Eur J Cardiovasc Prev Rehabil; 2004 Feb; 11(1):33-40. PubMed ID: 15167204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The vibratory perception threshold in young diabetic patients: associations with glycemia and puberty.
    Sosenko JM; Boulton AJ; Kubrusly DB; Weintraub JK; Skyler JS
    Diabetes Care; 1985; 8(6):605-7. PubMed ID: 4075949
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blood coagulation and fibrinolysis in obese NIDDM patients.
    Avellone G; Di Garbo V; Cordova R; Rotolo G; Abruzzese G; Raneli G; De Simone R; Bompiani GD
    Diabetes Res; 1994; 25(2):85-92. PubMed ID: 7648783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study.
    Eliasson M; Asplund K; Evrin PE; Lindahl B; Lundblad D
    Metabolism; 1994 Dec; 43(12):1579-86. PubMed ID: 7990715
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
    Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
    Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ethnicity and glycaemic control are major determinants of diabetic dyslipidaemia in Malaysia.
    Ismail IS; Nazaimoon W; Mohamad W; Letchuman R; Singaraveloo M; Hew FL; Shuguna C; Khalid BA
    Diabet Med; 2001 Jun; 18(6):501-8. PubMed ID: 11472471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Occurrence and interrelationships of complications in insulin-dependent diabetes in Finland.
    Ebeling P; Koivisto VA
    Acta Diabetol; 1997 Mar; 34(1):33-8. PubMed ID: 9134055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.